频域OCT在玻璃体腔注射曲安奈德治疗黄斑水肿中的临床应用

目的通过频域OCT观察玻璃体腔注射曲安奈德(TA)治疗黄斑水肿的临床疗效。方法回顾性分析46例眼科常规检查及经FFA和频域OCT查均确诊为黄斑水肿,视力≤0.6,黄斑中心凹厚度(CMT)≥250μm的患者46只眼纳入观察,进行玻璃体腔注射TA(4mg,0.1mL)治疗。比较治疗前和治疗后1d及1,2,4,8,12,24周最佳矫正视力(BCVA)改变;治疗前和治疗后1,2,4,8,12,24周的黄斑中心凹厚度(CMT)、黄斑中心容积(CMV)、黄斑区平均厚度(AVG)的改变。结果在治疗后视显提高,术后各时间点(P=0.000)均具有统计学意义,BCVA各点分别为:4周(0.3916±0.2564);8周(0.5668±0.1835);12周(0.5314±0.1996),视力基本持平,24周(0.3853±0.2024)缓慢下降。CMT方面,较基线比,在治疗后CMT明显降低,术后各时间点(P=0.000)均具有统计学意义。与基线相比,CMV、AVG两具有显著改变。BCVA分别与CMT、CMV、AVG呈负相关。结论玻璃体腔注射TA治疗黄斑水肿均可明显改善,减轻黄斑水肿。BCVA分别与CMT、CMV、AVG呈负相关,CMV、AVG也可反映治疗效果,但敏感性不及CMT

Clinical Application of IVTA Treatment for ME in RVO by Spectra Domain OCT

Objective To observe the efficiency of IVTA for the treatment of ME by spectra domain OCT.Methods A total of 46 eyes with ME were observed.All patients were diagnosed expecially by FFA and spectra domain OCT,with vision≤0.6 and CMT≥250μm.All received intravitreal injection of 4mg/0.1mL of TA.BCVA,CMT,CMV,and AVG were compared before and after treatment.Results After treatment,BCVA were significantly increased in each time point（P=0.000）,BCVA in 4（BCVA=0.3916±0.2564）,8（BCVA=0.5668±0.1835）,12（BCVA=0.5314±0.1996） weeks,were similar.After treatment,compared with baseline,the changes of CMT,CMV and AVG were significantly increased in each time point（P=0.000）.Conclusion IVTA for the treatment of ME could increase BCVA and reduce ME instinctively.CMT can reveal the effect of treatment better than CMV and AVG.